Presbyopia – epidemiological background, pathophysiology, and treatment methods, including laser refractive surgery Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
sie 6, 2025
Słowa kluczowe:
presbiopia, refractive surgery, multifocal intracocular lens, scleral procedures, presbymax, presbyond
##plugins.themes.bootstrap3.article.main##
Abstrakt
Presbiopia jest problemem dotykającym zazwyczaj osoby po 40. r.ż. Jest związana z utratą akomodacji, co wtórnie powoduje problem z widzeniem małych rzeczy z bliska. Jest wiele metod korygujących prezbiopię. Każda ma swoje wady i zalety. Artykuł opisuje epidemiologię, patofizjologię, niechirurgiczne i chirurgiczne metody korekcji prezbiopii ze szczególnym uwzględnieniem metod rogówkowych, a także twardówkowych i wewnątrzgałkowych związanych z wymianą soczewki.
##plugins.generic.usageStats.downloads##
##plugins.generic.usageStats.noStats##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Jasina G, Kozak M, Roszkowska AM. Presbyopia – epidemiological background, pathophysiology, and treatment methods, including laser refractive surgery. Ophthatherapy [Internet]. 6 sierpień 2025 [cytowane 30 maj 2026];12(2):171-6. Dostępne na: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/3078
Numer
Dział
Chirurgia i laseroterapia
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Mahrous A, Ciralsky JB, Lai EC. Revisiting monovision for presbyopia. Curr Opin Ophthalmol. 2018; 29(4): 313-7.
2. Zhang RY, Chen YG. New progress of excimer laser corneal refractive surgery for presbyopia. Zhonghua Yan Ke Za Zhi. 2022; 58(12): 1111-6.
3. Muhit M, Minto H, Parvin A et al. Prevalence of refractive error, presbyopia, and unmet need of spectacle coverage in a northern district of Bangladesh: Rapid Assessment of Refractive Error study. Ophthalmic Epidemiol. 2018; 25(2): 126-32.
4. Zebardast N, Friedman DS, Vitale S. The Prevalence and Demographic Associations of Presenting Near-Vision Impairment Among Adults Living in the United States. Am J Ophthalmol. 2017; 174: 134-44.
5. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res. 2019; 68: 124-43.
6. Lee Y, Kim JS, Park UC et al. Recent trends of refractive surgery rate and detailed analysis of subjects with refractive surgery: The 2008-2015 Korean National Health and Nutrition Examination Survey. PLoS One. 2021; 16(12): e0261347.
7. Ahn JH, Kim DH, Shyn KH. Investigation of the Changes in Refractive Surgery Trends in Korea. Korean J Ophthalmol. 2018; 32(1): 8-15.
8. Martin H, Stachs O, Guthoff R et al. Biomechanical investigations on accommodation of the eye. Ophthalmologe. 2018; 115(8): 649-54.
9. Schachar RA, Tello C, Cudmore DP et al. In vivo increase of the human lens equatorial diameter during accommodation. Am J Physiol. 1996; 271(3 Pt 2): R670-6.
10. Coleman DJ. Unified model for accommodative mechanism. Am J Ophthalmol. 1970; 69(6): 1063-79.
11. du Toit R. How to prescribe spectacles for presbyopia. Community Eye Health. 2006; 19(57): 12-3.
12. Durrie DS. The effect of different monovision contact lens powers on the visual function of emmetropic presbyopic patients (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006; 104: 366-401.
13. Waring GO, Price FW, Write D et al. Safety and Efficacy of AG-190584 in Individuals With Presbiopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. JAMA Ophthalmic. 2022; 140(4): 363-71.
14. U.S. Food and Drug Administration. NDA 214028/S-002. 2023 Mar .
15. U.S. Food and Drug Administration. NDA 217836. 2023 Oct.
16. Holland E, Karpecki P, Fingeret M et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024; 46(2): 104-13.
17. Mahrous A, Ciralsky JB, Lai EC. Revisiting monovision for presbyopia. Curr Opin Ophthalmol. 2018; 29(4): 313-7.
18. Lim DH, Chung ES, Kim MJ et al. Visual quality assessment after presbyopic laser in-situ keratomileusis. Int J Ophthalmol. 2018; 11(3): 462-9.
19. Fu D, Zhao J, Zhou XT. Objective optical quality and visual outcomes after the PresbyMAX monocular ablation profile. Int J Ophthalmol. 2020; 13(7): 1060-5.
20. Świątek J, Wierzbowska J, Worek D. Monowizja w różnych metodach korekcji presbiopii. Przegląd Okulistyczny. 2022; 4: 7-10.
21. Luger MH, Ewering T, Arba-Mosquera S. One-year experience in presbyopia correction with biaspheric multifocal central presbyopia laser in situ keratomileusis. Cornea. 2013; 32(5): 644-52.
22. Wierzbowska J, Pniakowska Z, Roszkowska AM. Contrast Sensitivity and Stereopsis Outcomes Following LASIK Presbyopia Correction Based on the Corneal Aberration Modulation or Corneal Multifocality Induction Methods: A Systematic Review. J Clin Med. 2025; 14: 871.
23. Hipsley A, Hall B, Rocha KM. Scleral surgery for the treatment of presbyopia: where are we today? Eye Vis (Lond). 2018; 5: 4.
24. Liu YC, Hall B, Lwin NC et al. Tissue Responses and Wound Healing following Laser Scleral Microporation for Presbyopia Therapy. Transl Vis Sci Technol. 2020; 9(4): 6.
25. Schmid R, Luedtke H. A Novel Concept of Correcting Presbyopia: First Clinical Results with a Phakic Diffractive Intraocular Lens. Clin Ophthalmol. 2020; 14: 2011-9.
26. Baïkoff G, Matach G, Fontaine A et al. Correction of presbyopia with refractive multifocal phakic intraocular lenses. J Cataract Refract Surg. 2004; 30(7): 1454-60.
27. Nijkamp MD, Dolders MG, de Brabander J et al. Effectiveness of multifocal intraocular lenses to correct presbyopia after cataract surgery: a randomized controlled trial. Ophthalmology. 2004; 111(10): 1832-9.
2. Zhang RY, Chen YG. New progress of excimer laser corneal refractive surgery for presbyopia. Zhonghua Yan Ke Za Zhi. 2022; 58(12): 1111-6.
3. Muhit M, Minto H, Parvin A et al. Prevalence of refractive error, presbyopia, and unmet need of spectacle coverage in a northern district of Bangladesh: Rapid Assessment of Refractive Error study. Ophthalmic Epidemiol. 2018; 25(2): 126-32.
4. Zebardast N, Friedman DS, Vitale S. The Prevalence and Demographic Associations of Presenting Near-Vision Impairment Among Adults Living in the United States. Am J Ophthalmol. 2017; 174: 134-44.
5. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res. 2019; 68: 124-43.
6. Lee Y, Kim JS, Park UC et al. Recent trends of refractive surgery rate and detailed analysis of subjects with refractive surgery: The 2008-2015 Korean National Health and Nutrition Examination Survey. PLoS One. 2021; 16(12): e0261347.
7. Ahn JH, Kim DH, Shyn KH. Investigation of the Changes in Refractive Surgery Trends in Korea. Korean J Ophthalmol. 2018; 32(1): 8-15.
8. Martin H, Stachs O, Guthoff R et al. Biomechanical investigations on accommodation of the eye. Ophthalmologe. 2018; 115(8): 649-54.
9. Schachar RA, Tello C, Cudmore DP et al. In vivo increase of the human lens equatorial diameter during accommodation. Am J Physiol. 1996; 271(3 Pt 2): R670-6.
10. Coleman DJ. Unified model for accommodative mechanism. Am J Ophthalmol. 1970; 69(6): 1063-79.
11. du Toit R. How to prescribe spectacles for presbyopia. Community Eye Health. 2006; 19(57): 12-3.
12. Durrie DS. The effect of different monovision contact lens powers on the visual function of emmetropic presbyopic patients (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006; 104: 366-401.
13. Waring GO, Price FW, Write D et al. Safety and Efficacy of AG-190584 in Individuals With Presbiopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. JAMA Ophthalmic. 2022; 140(4): 363-71.
14. U.S. Food and Drug Administration. NDA 214028/S-002. 2023 Mar .
15. U.S. Food and Drug Administration. NDA 217836. 2023 Oct.
16. Holland E, Karpecki P, Fingeret M et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024; 46(2): 104-13.
17. Mahrous A, Ciralsky JB, Lai EC. Revisiting monovision for presbyopia. Curr Opin Ophthalmol. 2018; 29(4): 313-7.
18. Lim DH, Chung ES, Kim MJ et al. Visual quality assessment after presbyopic laser in-situ keratomileusis. Int J Ophthalmol. 2018; 11(3): 462-9.
19. Fu D, Zhao J, Zhou XT. Objective optical quality and visual outcomes after the PresbyMAX monocular ablation profile. Int J Ophthalmol. 2020; 13(7): 1060-5.
20. Świątek J, Wierzbowska J, Worek D. Monowizja w różnych metodach korekcji presbiopii. Przegląd Okulistyczny. 2022; 4: 7-10.
21. Luger MH, Ewering T, Arba-Mosquera S. One-year experience in presbyopia correction with biaspheric multifocal central presbyopia laser in situ keratomileusis. Cornea. 2013; 32(5): 644-52.
22. Wierzbowska J, Pniakowska Z, Roszkowska AM. Contrast Sensitivity and Stereopsis Outcomes Following LASIK Presbyopia Correction Based on the Corneal Aberration Modulation or Corneal Multifocality Induction Methods: A Systematic Review. J Clin Med. 2025; 14: 871.
23. Hipsley A, Hall B, Rocha KM. Scleral surgery for the treatment of presbyopia: where are we today? Eye Vis (Lond). 2018; 5: 4.
24. Liu YC, Hall B, Lwin NC et al. Tissue Responses and Wound Healing following Laser Scleral Microporation for Presbyopia Therapy. Transl Vis Sci Technol. 2020; 9(4): 6.
25. Schmid R, Luedtke H. A Novel Concept of Correcting Presbyopia: First Clinical Results with a Phakic Diffractive Intraocular Lens. Clin Ophthalmol. 2020; 14: 2011-9.
26. Baïkoff G, Matach G, Fontaine A et al. Correction of presbyopia with refractive multifocal phakic intraocular lenses. J Cataract Refract Surg. 2004; 30(7): 1454-60.
27. Nijkamp MD, Dolders MG, de Brabander J et al. Effectiveness of multifocal intraocular lenses to correct presbyopia after cataract surgery: a randomized controlled trial. Ophthalmology. 2004; 111(10): 1832-9.